- Home
- ALLO vs KOD Comparison
ALLO vs KOD Comparison
Compare ALLO & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- KOD
- Stock Information
- Founded
- ALLO 2017
- KOD 2009
- Country
- ALLO United States
- KOD United States
- Employees
- ALLO N/A
- KOD N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLO Health Care
- KOD Health Care
- Exchange
- ALLO Nasdaq
- KOD Nasdaq
- Market Cap
- ALLO 231.9M
- KOD 198.4M
- IPO Year
- ALLO 2018
- KOD 2018
- Fundamental
- Price
- ALLO $1.05
- KOD $9.60
- Analyst Decision
- ALLO Strong Buy
- KOD Hold
- Analyst Count
- ALLO 10
- KOD 4
- Target Price
- ALLO $8.88
- KOD $11.75
- AVG Volume (30 Days)
- ALLO 5.8M
- KOD 763.3K
- Earning Date
- ALLO 08-13-2025
- KOD 08-13-2025
- Dividend Yield
- ALLO N/A
- KOD N/A
- EPS Growth
- ALLO N/A
- KOD N/A
- EPS
- ALLO N/A
- KOD N/A
- Revenue
- ALLO N/A
- KOD N/A
- Revenue This Year
- ALLO N/A
- KOD N/A
- Revenue Next Year
- ALLO $199.63
- KOD N/A
- P/E Ratio
- ALLO N/A
- KOD N/A
- Revenue Growth
- ALLO N/A
- KOD N/A
- 52 Week Low
- ALLO $0.86
- KOD $1.92
- 52 Week High
- ALLO $3.78
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- ALLO 38.79
- KOD 73.88
- Support Level
- ALLO $0.99
- KOD $9.45
- Resistance Level
- ALLO $1.21
- KOD $11.30
- Average True Range (ATR)
- ALLO 0.10
- KOD 0.85
- MACD
- ALLO -0.01
- KOD 0.24
- Stochastic Oscillator
- ALLO 20.59
- KOD 89.19
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.